Rallybio(US:RLYB)2025-03-13 12:11Financial Performance - Revenue for Q4 2024 was $38 thousand, and total revenue for the year ended December 31, 2024, was $0.6 million, compared to no revenue in the same periods in 2023[12] - R&D expenses decreased to $7.4 million in Q4 2024 from $15.9 million in Q4 2023, and for the full year, R&D expenses were $41.5 million compared to $53.5 million in 2023[12] - G&A expenses were $4.3 million for Q4 2024, down from $5.2 million in Q4 2023, and totaled $19.6 million for the year compared to $25.4 million in 2023[12] - Net loss for Q4 2024 was $11.0 million, or $0.25 per share, compared to a net loss of $20.2 million, or $0.50 per share, in Q4 2023[13] - Cash, cash equivalents, and marketable securities as of December 31, 2024, were $65.5 million, providing a runway into the second half of 2026[6] Clinical Development - RLYB212 Phase 2 trial dosing is underway, with key data readouts expected in Q2 and Q3 2025[6] - RLYB116 is on track to enter a confirmatory PK/PD study in Q2 2025, with data anticipated in the second half of 2025[6] - More than 14,300 pregnant women were screened in the FNAIT natural history study as of January 31, 2025[7] - The company plans to present interim data from the FNAIT natural history study in mid-2025[7] - REV102, an ENPP1 inhibitor, is advancing toward a Phase 1 study expected to start in 2026[12]